Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
BACKGROUND AND AIM:Treatment of hepatitis C with direct-acting antiviral agents (DAA) has few side effects. Although pivotal studies suggested that DAA were safe in patients with psychiatric diseases who could not be treated with previous antiviral therapies, their effects on anxiety and depression...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0208112 |
| _version_ | 1818361896574648320 |
|---|---|
| author | Marta Gallach Mercedes Vergara Joao Pedro da Costa Mireia Miquel Meritxell Casas Jordi Sanchez-Delgado Blai Dalmau Núria Rudi Isabel Parra Teresa Monllor Meritxell Sanchez-Lloansí Angelina Dosal Oliver Valero Xavier Calvet |
| author_facet | Marta Gallach Mercedes Vergara Joao Pedro da Costa Mireia Miquel Meritxell Casas Jordi Sanchez-Delgado Blai Dalmau Núria Rudi Isabel Parra Teresa Monllor Meritxell Sanchez-Lloansí Angelina Dosal Oliver Valero Xavier Calvet |
| author_sort | Marta Gallach |
| collection | DOAJ |
| description | BACKGROUND AND AIM:Treatment of hepatitis C with direct-acting antiviral agents (DAA) has few side effects. Although pivotal studies suggested that DAA were safe in patients with psychiatric diseases who could not be treated with previous antiviral therapies, their effects on anxiety and depression have not yet been analysed in clinical practice. The aim of our study was to analyse anxiety and depression in the setting of DAA treatment in a clinical practice series. METHODS:All patients starting DAA treatment between November 1, 2014 and October 31, 2015 were eligible. Patients completed the Hospital Anxiety and Depression scale at different times during treatment. The results were plotted on line graphs and evaluated using a linear regression model with repeated measures. RESULTS:One hundred and forty-five patients were included (11% with major psychiatric disorders; 32% on psychiatric treatment). Sustained virologic response (SVR) was achieved in 97.3% of cases. Anxiety and depression measures did not differ between time points. No differences between patients on psychiatric treatment or with advanced fibrosis or cirrhosis were found at any time point analysed. CONCLUSION:DAA treatment had no impact on anxiety or depression during or after chronic hepatitis C infection treatment, even in high-risk patients with major psychiatric disorders. |
| first_indexed | 2024-12-13T21:23:58Z |
| format | Article |
| id | doaj.art-91db3feabd944fe8b221f4d7fdf932bc |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T21:23:58Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-91db3feabd944fe8b221f4d7fdf932bc2022-12-21T23:31:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011312e020811210.1371/journal.pone.0208112Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.Marta GallachMercedes VergaraJoao Pedro da CostaMireia MiquelMeritxell CasasJordi Sanchez-DelgadoBlai DalmauNúria RudiIsabel ParraTeresa MonllorMeritxell Sanchez-LloansíAngelina DosalOliver ValeroXavier CalvetBACKGROUND AND AIM:Treatment of hepatitis C with direct-acting antiviral agents (DAA) has few side effects. Although pivotal studies suggested that DAA were safe in patients with psychiatric diseases who could not be treated with previous antiviral therapies, their effects on anxiety and depression have not yet been analysed in clinical practice. The aim of our study was to analyse anxiety and depression in the setting of DAA treatment in a clinical practice series. METHODS:All patients starting DAA treatment between November 1, 2014 and October 31, 2015 were eligible. Patients completed the Hospital Anxiety and Depression scale at different times during treatment. The results were plotted on line graphs and evaluated using a linear regression model with repeated measures. RESULTS:One hundred and forty-five patients were included (11% with major psychiatric disorders; 32% on psychiatric treatment). Sustained virologic response (SVR) was achieved in 97.3% of cases. Anxiety and depression measures did not differ between time points. No differences between patients on psychiatric treatment or with advanced fibrosis or cirrhosis were found at any time point analysed. CONCLUSION:DAA treatment had no impact on anxiety or depression during or after chronic hepatitis C infection treatment, even in high-risk patients with major psychiatric disorders.https://doi.org/10.1371/journal.pone.0208112 |
| spellingShingle | Marta Gallach Mercedes Vergara Joao Pedro da Costa Mireia Miquel Meritxell Casas Jordi Sanchez-Delgado Blai Dalmau Núria Rudi Isabel Parra Teresa Monllor Meritxell Sanchez-Lloansí Angelina Dosal Oliver Valero Xavier Calvet Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. PLoS ONE |
| title | Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. |
| title_full | Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. |
| title_fullStr | Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. |
| title_full_unstemmed | Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. |
| title_short | Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. |
| title_sort | impact of treatment with direct acting antivirals on anxiety and depression in chronic hepatitis c |
| url | https://doi.org/10.1371/journal.pone.0208112 |
| work_keys_str_mv | AT martagallach impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT mercedesvergara impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT joaopedrodacosta impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT mireiamiquel impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT meritxellcasas impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT jordisanchezdelgado impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT blaidalmau impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT nuriarudi impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT isabelparra impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT teresamonllor impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT meritxellsanchezlloansi impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT angelinadosal impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT olivervalero impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc AT xaviercalvet impactoftreatmentwithdirectactingantiviralsonanxietyanddepressioninchronichepatitisc |